The FDA approved Sept. 6 the first treatment for a rare interstitial lung disease associated with systemic sclerosis or scleroderma.
The treatment, called Ofev, slows the rate of decline in pulmonary function in adults with the rare lung condition.The FDA granted approval of Ofev to treat the disease to Boehringer Ingelheim.
Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis.
Read the full report here.